Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 11/20 | 1.00 |
| ▸ | CNR1 | P21554 | 8/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | CASP1 | P29466 | 2/20 | 1.00 |
| ▸ | CASP7 | P55210 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | BCHE | P06276 | 3/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7123280 | 0.95 | CNR2 (0.90) | CNR2CNR1CYP3A4MAPTCASP1 | |
| SCHEMBL8270651 | 0.92 | CNR2 (0.86) | CNR2CNR1CYP3A4MAPTCASP1 | |
| SCHEMBL6746977 | 0.91 | CNR2 (0.82) | CNR2CNR1CYP3A4MAPTCASP1 | |
| SCHEMBL684780 | 0.90 | CNR2 (0.81) | CNR2CNR1CYP3A4MAPTCASP1 | |
| SCHEMBL6748804 | 0.86 | CNR2 (0.75) | CNR2CNR1CYP3A4MAPTCASP1 | |
| SCHEMBL7640834 | 0.85 | CNR2 (0.74) | CNR2CNR1CYP3A4MAPTCASP1 | |
| SCHEMBL7638171 | 0.81 | CNR2 (0.69) | CNR2CNR1CYP3A4MAPTCASP1 | |
| SCHEMBL4653103 | 0.81 | CNR1 (0.67) | CNR2CNR1CYP3A4MAPTCASP1 | |
| SCHEMBL5024772 | 0.79 | CYP3A4 (0.65) | CNR2CNR1CYP3A4MAPTCASP1 | |
| SCHEMBL24046767 | 0.79 | CYP3A4 (0.79) | CNR2CNR1CYP3A4MAPTCASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022204414-A1 | FORMULATIONS AND KITS FOR THE DIAGNOSTIC EVALUATION OF INFECTIOUS DISEASES AND METHODS THEREOF | VYRIPHARM ENTERPRISES, INC. (US) | 2022-09-29 | — | — | WO | claimed |
| WO-2022204419-A1 | SYNTHETIC CANNABINOID COMBINATION THERAPY COMPOSITIONS AND METHODS FOR PERSONALIZED AND TARGETED THERAPIES INCLUDING THE TREATMENT OF INFECTIOUS DISEASES | VYRIPHARM ENTERPRISES, INC. (US) | 2022-09-29 | — | — | WO | claimed |
| EP-2739262-B1 | USE OF A CB1 RECEPTOR ANTAGONIST AS A WHITENING AND/OR ANTI-BROWNING AGENT FOR KERATIN MATERIAL | OREAL (FR) | 2017-09-27 | — | — | EP | claimed |
| EP-2739262-A2 | USE OF A CB1 RECEPTOR ANTAGONIST AS A WHITENING AND/OR ANTI-BROWNING AGENT FOR KERATIN MATERIAL | L'OREAL (FR) | 2014-06-11 | — | — | EP | claimed |
| US-20140142106-A1 | METHOD FOR TREATING PERITONEAL FIBROSIS | TAIPEI VETERANS GENERAL HOSPITAL (TW) | 2014-05-22 | — | — | US | claimed |
| WO-2013021129-A2 | USE OF A CB1 RECEPTOR ANTAGONIST AS A WHITENING AND/OR ANTI-BROWNING AGENT FOR KERATIN MATERIAL | L'OREAL (FR) | 2013-02-14 | — | — | WO | claimed |
| EP-2084127-A1 | DIARYL, DIPYRIDINYL AND ARYL-PYRIDINYL DERIVATIVES AND USES THEREOF | Pfizer Products Inc. (US) | 2009-08-05 | — | — | EP | claimed |
| EP-2064199-A1 | DIARYL ETHER DERIVATIVES AND USES THEREOF | Pfizer Products Inc. (US) | 2009-06-03 | — | — | EP | claimed |
| WO-2008059335-A1 | DIARYL, DIPYRIDINYL AND ARYL-PYRIDINYL DERIVATIVES AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2008-05-22 | — | — | WO | claimed |
| US-20080070887-A1 | Diaryl Ether Derivatives and Uses Thereof | PFIZER INC | 2008-03-20 | — | — | US | claimed |
| WO-2008032156-A1 | DIARYL ETHER DERIVATIVES AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2008-03-20 | — | — | WO | claimed |
| EP-1890767-A2 | COMBINATION OF A CANNABINOID-1- RECEPTOR-ANTAGONIST AND A MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR FOR TREATING OBESITY OR MAINATAINING WEIGHT LOSS | Pfizer Products Inc. (US) | 2008-02-27 | — | — | EP | claimed |
| WO-2007039797-A1 | USE OF CANNABINOID RECEPTOR-1 ANTAGONIST FOR TREATING INFLAMMATION AND ARTHRITIS | PFIZER PRODUCTS INC. (US) | 2007-04-12 | — | — | WO | claimed |
| WO-2006129193-A2 | COMBINATION OF A CANNABINOID-1- RECEPTOR-ANTAGONIST AND A MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR FOR TREATING OBESITY OR MAINATAINING WEIGHT LOSS | PFIZER PRODUCTS INC. (US) | 2006-12-07 | — | — | WO | claimed |
| US-20060270655-A1 | Combination therapy for treating obesity or maintaining weight loss | SWICK ANDREW G | 2006-11-30 | — | — | US | claimed |
| US-20060160776-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2006-07-20 | — | — | US | claimed |
| WO-2004105699-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A CANNABINOID AGENT FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2004-12-09 | — | — | WO | claimed |
| US-20240024403-A1 | Compositions and Methods for Managing Weight | UNIGEN, INC. (US) | 2024-01-25 | — | — | US | disclosed |
| US-5596106-A | ARYL-BENZO(B)THIOPHENE OR BENZO(B)FURAN COMPOUNDS | ELI LILLY AND COMPANY (US) | 1997-01-21 | — | — | US | disclosed |
| WO-1996002248-A1 | CANNABINOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1996-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070887-A1 | Diaryl Ether Derivatives and Uses Thereof | OPRD1, OPRK1, OPRL1 | CNR2 20/4885CNR1 13/4885CYP3A4 451/4885 |
| US-20240024403-A1 | Compositions and Methods for Managing Weight | LIPE, PNLIP, LIPC | CNR2 13/4885CNR1 12/4885CYP3A4 795/4885 |
| US-20060160776-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage | CNR2, CNR1, PTGS2 | CNR2 1/4885CNR1 2/4885CYP3A4 2623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.